Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition
BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. and Asia, Arbele stood out for its groundbreaking research in CDH17-targeted immunotherapy and antibody-drug conjugates (ADCs). Arbele is developing novel treatments...
Concord Healthcare Announces Completion of China’s First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 15, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary...
Xinhua Silk Road: E. China city Longkou moves to forefront of sustainable health & wellness dev. in China
BEIJING, July 26, 2025 /PRNewswire/ -- Longkou, a county-level city in east China, has recently been included into China's top 100 counties by sustainable development capacity of health and wellness industry, according to the annual report on health and wellness industry of China (2024-2025). Longkou is an early starter in bolstering health and wellness industry. It is a demonstrative...
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and...
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA). 7MW4911 is an investigational CDH17-targeting ADC developed...
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 DEEs are the most severe rare epilepsies, characterized by drug-resistant seizures, frequent epileptic activity on EEG...
‘CART BP pro’ Opens a New Paradigm in Blood Pressure Management, Maintaining Accuracy Across Arm Positions
SEOUL, South Korea, Sept. 5, 2025 /PRNewswire/ -- At the European Society of Cardiology (ESC) Congress 2025, held in Madrid from August 29 to September 1, Sky Labs presented new clinical findings on CART BP pro, its cuffless, ring-type blood pressure monitor. The device demonstrated consistent accuracy even when the arm was...
Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End
1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and...
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically meaningful reductions in inflammation and ocular pain observed as early as Day 3 Very favorable safety profile with low adverse event rate in active groups WENZHOU, China and SAN DIEGO, Dec....
LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System
Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring Web-based system displays multiple patient physiological data continuously, with visual alarms and alert notifications for streamlined patient care Developed to support...
